Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 201–300 of 1,016
Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients
Chariou, P. L., Ortega-Rivera, O. A., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c00173 · Cited by 212
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 209
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak, M., Wiktorowska-Owczarek, A., & Stanczak, A. (2021) · Molecules · doi:10.3390/molecules26092601 · Cited by 197
The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma
Das, P. K., Islam, F., & Lam, A. K. (2020) · Cells · doi:10.3390/cells9061392 · Cited by 210
“For example, mutations in key signalling pathway molecules, the increased expression of anti-apoptotic proteins, the presence of quiescent and/or resistant tumour cells or the over-activation of drug efflux pumps are all potential causes of therapy failure [4,5].”
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective: Miniperspective
Myers, S. H., Brunton, V. G., & Unciti-Broceta, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01273 · Cited by 203
Assanhou, A. G., Li, W., Zhang, L., Xue, L., Kong, L., Sun, H., Mo, R., & Zhang, C. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.022 · Cited by 207
“The occurrence of multidrug resistance (MDR) remains the main issue and the major challenge in cancer therapy [1].”
Chiang, K., Zielinska, A. E., Shaaban, A. M., Sanchez-Bailon, M. P., Jarrold, J., Clarke, T. L., Zhang, J., Francis, A., Jones, L. J., Smith, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.096 · Cited by 204
“Importantly, these cells have slow rates of division, high expression of drug efflux pumps, and high capacity for DNA repair (Holohan et al., 2013) and are thus relatively drug resistant.”
BackgroundMolecular and cellular paradigms of multidrug resistance in cancer
Vaidya, F. U., Sufiyan Chhipa, A., Mishra, V., Gupta, V. K., Rawat, S. G., Kumar, A., & Pathak, C. (2022) · Cancer Reports · doi:10.1002/cnr2.1291 · Cited by 197
Small‐Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery
Li, G., Sun, B., Li, Y., Luo, C., He, Z., & Sun, J. (2021) · Small · doi:10.1002/smll.202101460 · Cited by 205
Doostmohammadi, A., Jooya, H., Ghorbanian, K., Gohari, S., & Dadashpour, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01607-9 · Cited by 187
“Under the treatment pressure, cancer cells can adapt molecular and cellular mechanisms to evade the effects of the drug, often evolve into more aggressive or metastasis phenotypes, and limit the success of monotherapies [28].”
BackgroundEmerging role of PI3K/AKT in tumor-related epigenetic regulation
Yang, Q., Jiang, W., & Hou, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.04.001 · Cited by 202
Charge reversal nano-systems for tumor therapy
Zhang, P., Chen, D., Li, L., & Sun, K. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01221-8 · Cited by 178
Hojjat-Farsangi, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813768 · Cited by 203
“Resistance to the current targeted therapies, including SMIs, can be divided into the intrinsic and acquired resistance [151].”
BackgroundInfluentialAstrocytes, the rising stars of the glioblastoma microenvironment
Brandao, M., Simon, T., Critchley, G., & Giamas, G. (2019) · Glia · doi:10.1002/glia.23520 · Cited by 208
Zhang, Y., Sha, R., Zhang, L., Zhang, W., Jin, P., Xu, W., Ding, J., Lin, J., Qian, J., Yao, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06529-y · Cited by 204
CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors
Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205
“There has been extensive focus on tumor cell-intrinsic pathways that allow cells to survive therapy (Holohan et al., 2013).”
BackgroundLiu, J., Yuan, Y., Cheng, Y., Fu, D., Chen, Z., Wang, Y., Zhang, L., Yao, C., Shi, L., Li, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11856 · Cited by 202
The two sides of chromosomal instability: drivers and brakes in cancer
Hosea, R., Hillary, S., Naqvi, S., Wu, S., & Kasim, V. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01767-7 · Cited by 189
“27,404 While the molecular mechanism of tumor cells drug resistance are complex and have not been totally elucidated, CIN, as a fuel of tumor evolution that causes intratumor heterogeneity, has been assumed as one of the major reason for drug resistance.”
BackgroundRole of the NF-κB signaling pathway in the pathogenesis of colorectal cancer
Soleimani, A., Rahmani, F., Ferns, G. A., Ryzhikov, M., Avan, A., & Hassanian, S. M. (2020) · Gene · doi:10.1016/j.gene.2019.144132 · Cited by 203
Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance
De Angelis, M. L., Francescangeli, F., La Torre, F., & Zeuner, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00626 · Cited by 206
Autophagy and doxorubicin resistance in cancer
Chen, C., Lu, L., Yan, S., Yi, H., Yao, H., Wu, D., He, G., Tao, X., & Deng, X. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000572 · Cited by 202
Time-resolved protein activation by proximal decaging in living systems
Wang, J., Liu, Y., Liu, Y., Zheng, S., Wang, X., Zhao, J., Yang, F., Zhang, G., Wang, C., & Chen, P. R. (2019) · Nature · doi:10.1038/s41586-019-1188-1 · Cited by 205
A Pharmacogenomic Landscape in Human Liver Cancers
Qiu, Z., Li, H., Zhang, Z., Zhu, Z., He, S., Wang, X., Wang, P., Qin, J., Zhuang, L., Wang, W., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.001 · Cited by 203
“of predictive biomarkers has been proposed to select responsive patients (Holohan et al., 2013), which apparently requires systematic knowledge of pharmacogenomic landscape in liver cancers.”
BackgroundTargeted Therapy and Mechanisms of Drug Resistance in Breast Cancer
Kinnel, B., Singh, S. K., Oprea-Ilies, G., & Singh, R. (2023) · Cancers · doi:10.3390/cancers15041320 · Cited by 184
“On the other hand, acquired resistance can result from the activation of proto-oncogenes, alterations in gene expression due to mutations or epigenetic markers, and changes in the tumor microenvironment after treatment [12].”
BackgroundInfluentialMolecular mechanisms of drug resistance in ovarian cancer
Norouzi‐Barough, L., Sarookhani, M. R., Sharifi, M., Moghbelinejad, S., Jangjoo, S., & Salehi, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26289 · Cited by 200
Liu, S., Pan, J., Liu, J., Ma, Y., Qiu, F., Mei, L., Zeng, X., & Pan, G. (2018) · Small · doi:10.1002/smll.201703968 · Cited by 200
Wan, G., Chen, B., Li, L., Wang, D., Shi, S., Zhang, T., Wang, Y., Zhang, L., & Wang, Y. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.002 · Cited by 199
Hes1: a key role in stemness, metastasis and multidrug resistance
Liu, Z.-H., Dai, X.-M., & Du, B. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1016662 · Cited by 201
“capacity and quiescence.(53,54) This may provide a new avenue to target CSCs, as the Hes1 anti-drug effect has been recently discovered.”
BackgroundCytokines in cancer drug resistance: Cues to new therapeutic strategies
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z.-S., Fu, L., & Huang, R.-P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.005 · Cited by 195
Zhang, K., Erkan, E. P., Jamalzadeh, S., Dai, J., Andersson, N., Kaipio, K., Lamminen, T., Mansuri, N., Huhtinen, K., Carpén, O., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1831 · Cited by 197
Xiao, Q., Zhao, W., Wu, C., Wang, X., Chen, J., Shi, X., Sha, S., Li, J., Liang, X., Yang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105274 · Cited by 188
Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Chacon Castro, M. D. C., Deese, A. R., & Zhang, L. (2022) · Cancers · doi:10.3390/cancers14194562 · Cited by 183
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Wu, H.-L., Gong, Y., Ji, P., Xie, Y.-F., Jiang, Y.-Z., & Liu, G.-Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01263-x · Cited by 186
“Although chemotherapy is still the keystone of all cancer treatment therapies to date in the adjuvant setting, the effectiveness of chemotherapy is hampered by drug resistance and adverse side effects [163, 164].”
BackgroundIn vitro and in vivo anticancer efficacy potential of Quercetin loaded polymeric nanoparticles
Baksi, R., Singh, D. P., Borse, S. P., Rana, R., Sharma, V., & Nivsarkar, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.106 · Cited by 185
Ippolito, M. R., Martis, V., Martin, S., Tijhuis, A. E., Hong, C., Wardenaar, R., Dumont, M., Zerbib, J., Spierings, D. C. J., Fachinetti, D., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.07.006 · Cited by 188
“A major determinant of chemoresistance, often seen in cancer cells, is provided by the overexpression of the therapeutic drug target (Holohan et al., 2013).”
BackgroundChemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Park, Y. H., Lal, S., Lee, J. E., Choi, Y.-L., Wen, J., Ram, S., Ding, Y., Lee, S.-H., Powell, E., Lee, S. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19933-0 · Cited by 186
Zhao, Q., Huang, L., Qin, G., Qiao, Y., Ren, F., Shen, C., Wang, S., Liu, S., Lian, J., Wang, D., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.009 · Cited by 191
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
“Drug resistance to targeted therapies in cancer can be classified as primary or acquired (Figure 1A) [8,9].”
BackgroundFive-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells
Abrams, R. P., Carroll, W. L., & Woerpel, K. A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00900 · Cited by 187
“majority induce cell death by initiating the mitochondrial pathway of apoptosis.(3,4) This common”
Ahmad, A., Khan, F., Mishra, R. K., & Khan, R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00511 · Cited by 186
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. A., Ortiz-Sánchez, E., & García-Carrancá, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 180
“Mechanisms of Chemoresistance Resistance to chemotherapy is a major cause of cancer-associated death that can occur due to several factors, including enhanced drug efflux and metabolic reprograming (Holohan et al., 2013).”
BackgroundJung, K., Corrigan, N., Wong, E. H. H., & Boyer, C. (2022) · Advanced Materials · doi:10.1002/adma.202105063 · Cited by 183
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., Opatrilova, R., Kruzliak, P., Stefanicka, P., & Büsselberg, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.108 · Cited by 184
Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer
Zhu, L., Zhu, Y., Han, S., Chen, M., Song, P., Dai, D., Xu, W., Jiang, T., Feng, L., Shin, V. Y., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1585-2 · Cited by 186
Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer
Wu, H.-T., Zhong, H.-T., Li, G.-W., Shen, J.-X., Ye, Q.-Q., Zhang, M.-L., & Liu, J. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02240-z · Cited by 182
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
Balmus, G., Pilger, D., Coates, J., Demir, M., Sczaniecka-Clift, M., Barros, A. C., Woods, M., Fu, B., Yang, F., Chen, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07729-2 · Cited by 184
The role of polyphenols in overcoming cancer drug resistance: a comprehensive review
Maleki Dana, P., Sadoughi, F., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00301-9 · Cited by 186
“Both acquired and intrinsic processes can lead to chemoresistance in cancer cells [4].”
BackgroundCastilho, R., Squarize, C., & Almeida, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071506 · Cited by 183
“CSCs display high expression of drug efflux pumps, such as ATP-binding cassette (ABC) transporter family proteins, which are important for efflux of drugs across the plasma membrane [155,167].”
BackgroundmACPpred: A Support Vector Machine-Based Meta-Predictor for Identification of Anticancer Peptides
Boopathi, V., Subramaniyam, S., Malik, A., Lee, G., Manavalan, B., & Yang, D.-C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081964 · Cited by 184
“Additionally, there is a growing concern that cancer cells may develop resistance to chemotherapy and molecularly-targeted therapies [10].”
BackgroundDormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer
Vallette, F. M., Olivier, C., Lézot, F., Oliver, L., Cochonneau, D., Lalier, L., Cartron, P.-F., & Heymann, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.004 · Cited by 190
“Interestingly, many known mechanisms of resistance in cancer appear to be related to similar pathways [86] (Fig.”
BackgroundAPR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
“Much effort has focused on the ABC-drug transporters that have been shown to be overexpressed in many cancer cell lines as well as clinical samples, and cause reduced drug concentrations in cancer cells.(43) Co-administration of efflux pump inhibitors increases intracellular drug concentrations in vitro.”
BackgroundBaghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, N., Putra, W. E., Endo, D., Watari, H., Sakuragi, N., Hida, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1170 · Cited by 180
“In the past few decades, several studies have underlined intrinsic mechanisms that occur inside cancer cells and contribute to chemoresistance such as the induction of antiapoptotic regulators, ABC transporters, aberrantNF-kBactivities, andDNAdamagemachinery (2, 3).”
BackgroundPrinciples and mechanisms of non-genetic resistance in cancer
Bell, C. C., & Gilan, O. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 182
Jin, X., Tang, J., Qiu, X., Nie, X., Ou, S., Wu, G., Zhang, R., & Zhu, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01825-7 · Cited by 176
“Current cancer treatment strategies aim to selectively eliminate cancer cells without causing harm to healthy cells [2].”
BackgroundThe pro-tumorigenic host response to cancer therapies
Shaked, Y. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 181
Zhang, P., Gao, D., An, K., Shen, Q., Wang, C., Zhang, Y., Pan, X., Chen, X., Lyv, Y., Cui, C., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0426-3 · Cited by 179
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2106) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 177
“Reasons for acquisition of anticancer drug resistance include enhanced expression of transporters that increases anticancer drugs efflux, alterations in drug metabolism, mutations of drug targets and the activation of survival or inactivation of downstream death signaling pathways (Figure 1) [1].”
BackgroundInfluentialAli, M. R. K., Wu, Y., Tang, Y., Xiao, H., Chen, K., Han, T., Fang, N., Wu, R., & El-Sayed, M. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703151114 · Cited by 176
“Moreover, in many cases, the anticancer drugs that target specific proteins might lose their efficacy after several months of treatment due to mutations of the proteins that result in the rise of drug resistance in cancer cells (11, 12).”
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Bell, C. C., Fennell, K. A., Chan, Y.-C., Rambow, F., Yeung, M. M., Vassiliadis, D., Lara, L., Yeh, P., Martelotto, L. G., Rogiers, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10652-9 · Cited by 183
Ilié, M., Hofman, V., Long-Mira, É., Bordone, O., Selva, É., Washetine, K., Marquette, C., & Hofman, V. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.08.11 · Cited by 175
Mechanisms of acquired tumor drug resistance
Aleksakhina, S. N., Kashyap, A., & Imyanitov, E. N. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188310 · Cited by 177
ACPred-Fuse: fusing multi-view information improves the prediction of anticancer peptides
Rao, B., Zhou, C., Zhang, G., Su, R., & Wei, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz088 · Cited by 179
Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme
Jena, L., McErlean, E., & McCarthy, H. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00679-2 · Cited by 176
“tance can develop during treatment of tumours that were initially sensitive and can be caused by mutations arising during treatment, as well as through various other adaptive responses, such as increased expression of the therapeutic target and activation of alternative compensatory signalling pathways [57].”
BackgroundGlutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis
Zhu, Z., Du, S., Du, Y., Ren, J., Ying, G., & Yan, Z. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14250 · Cited by 175
“…resistance-associated protein, and lung resistance-associated protein (Massey et al. 2014), enhanced DNA repair and anti-apoptotic activity, metabolism reprogramming, abnormal microvasculature, and microenvironments, contribute to drug resistance (Holohan et al. 2013; Rebucci and Michiels 2013).”
BackgroundZhang, R. X., Ahmed, T., Li, L. Y., Li, J., Abbasi, A. Z., & Wu, X. Y. (2017) · Nanoscale · doi:10.1039/c6nr08486a · Cited by 174
Shen, W., Liu, W., Yang, H., Zhang, P., Xiao, C., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.011 · Cited by 176
“T he acquired MDR can be developed during multiple co urses of treatment with chemotherapeutic agents through a nu mber of molecular mechanisms, including decreased d rug influx, excessive drug efflux, mutation of drug tar gets, activation of DNA repair, and deregulation of apoptosis [3, 4].”
BackgroundTsai, C.-F., Wang, Y.-T., Yen, H.-Y., Tsou, C.-C., Ku, W.-C., Lin, P.-Y., Chen, H.-Y., Nesvizhskii, A. I., Ishihama, Y., & Chen, Y.-J. (2015) · Nature Communications · doi:10.1038/ncomms7622 · Cited by 176
A mitochondria-targeting magnetothermogenic nanozyme for magnet-induced synergistic cancer therapy
Shen, J., Rees, T. W., Zhou, Z., Yang, S., Ji, L., & Chao, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120079 · Cited by 172
An update on the potential mechanism of gallic acid as an antibacterial and anticancer agent
Keyvani‐Ghamsari, S., Rahimi, M., & Khorsandi, K. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3615 · Cited by 165
“Drug resistance can develop as inherent resistance of cancer cells to the drug or as acquired during treatment which the growth of resistant cells leads to treatment failure (Holohan et al., 2013).”
BackgroundJia, S., Zhang, R., Li, Z., & Li, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17184 · Cited by 171
“Nowadays, targeted therapy is one of the principal modes of cancer treatment, which has had varying degrees of success owing to the diverse range of resistance mechanisms [5, 6].”
BackgroundMarine Sponge Natural Products with Anticancer Potential: An Updated Review
Calcabrini, C., Catanzaro, E., Bishayee, A., Turrini, E., & Fimognari, C. (2017) · Marine Drugs · doi:10.3390/md15100310 · Cited by 166
“resistance against anticancer drugs, such as vinca alkaloids, anthracyclines, taxanes, camptothecines, and epipodophyllotoxins [152].”
BackgroundPolymer encapsulation of ruthenium complexes for biological and medicinal applications
Villemin, E., Ong, Y. C., Thomas, C. M., & Gasser, G. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0088-0 · Cited by 167
Nanostructured SERS-electrochemical biosensors for testing of anticancer drug interactions with DNA
Ilkhani, H., Hughes, T., Li, J., Zhong, C. J., & Hepel, M. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.01.068 · Cited by 169
Yan, J., Dang, Y., Liu, S., Zhang, Y., & Zhang, G. (2016) · Tumor Biology · doi:10.1007/s13277-016-5448-5 · Cited by 168
“As the most important agent in chemotherapy of various human cancers, previous studies demonstrated that the molecular mechanisms of cisplatin resistance included reduction of intracellular cisplatin accumulation, ineffective induction of cell death, and enhancement of DNA damage repair [2, 3].”
BackgroundCurcumin in combination with anti-cancer drugs: A nanomedicine review
Batra, H., Pawar, S., & Bahl, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.005 · Cited by 166
Agarwal, R., Jurney, P., Raythatha, M., Singh, V., Sreenivasan, S. V., Shi, L., & Roy, K. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500441 · Cited by 169
Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery
Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168
Yan, C., Luo, L., Guo, C.-Y., Goto, S., Urata, Y., Shao, J.-H., & Li, T.-S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.018 · Cited by 169
Cancer Stem Cell Plasticity Drives Therapeutic Resistance
Doherty, M., Smigiel, J., Junk, D., & Jackson, M. (2016) · Cancers · doi:10.3390/cancers8010008 · Cited by 160
“CSCs also express lower levels of pro-apoptotic proteins, such as caspase-8, and elevated levels of drug efflux pumps, such as MDR-1 and the p-glycoproteins [44], which transport chemotherapeutics out of the cell, rendering them ineffective [45,46].”
BackgroundPan, Q., Nie, C., Hu, Y., Yi, J., Liu, C., Zhang, J., He, M., He, M., Chen, T., & Chu, X. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b20707 · Cited by 164
Transcription Factors in Cancer Development and Therapy
Vishnoi, K., Viswakarma, N., Rana, A., & Rana, B. (2020) · Cancers · doi:10.3390/cancers12082296 · Cited by 164
“In most solid tumors, the rapidly growing cells generate regions of hypoxia because of aberrant vascularization and inadequate oxygen [41], which often lead to more aggressive tumor behaviors [42,43], therapy resistance and poor prognosis [44,45].”
BackgroundBioinorganic antimicrobial strategies in the resistance era
Regiel-Futyra, A., Dąbrowski, J. M., Mazuryk, O., Śpiewak, K., Kyzioł, A., Pucelik, B., Brindell, M., & Stochel, G. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.005 · Cited by 164
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Leary, M., Heerboth, S., Lapinska, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 165
“Downregulation of a particular gene in this family, UGT1A1 is negatively regulated via DNA methylation, and is implicated in resistance to irinotecan (topoisomerase inhibitor) [32,38,39].”
BackgroundInfluentialBCL2: A promising cancer therapeutic target
Radha, G., & Raghavan, S. C. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.06.004 · Cited by 163
Qiao, Y., Zhang, C., Li, A., Wang, D., Luo, Z., Ping, Y., Zhou, B., Liu, S., Li, H., Yue, D., et al. (2018) · Oncogene · doi:10.1038/onc.2017.387 · Cited by 166
Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells
Chowdhury, P., Nagesh, P. K. B., Hatami, E., Wagh, S., Dan, N., Tripathi, M. K., Khan, S., Hafeez, B. B., Meibohm, B., Chauhan, S. C., et al. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.09.072 · Cited by 162
Lan, J.-S., Liu, L., Zeng, R.-F., Qin, Y.-H., Hou, J.-W., Xie, S.-S., Yue, S., Yang, J., Ho, R. J. Y., Ding, Y., et al. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127212 · Cited by 165
Bui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 194
“due to insufficient efficacy, unwanted side effects on the tumor-bearing host, or the development of resistance to the therapy [2,3].”
BackgroundRational Design of Biomaterials to Potentiate Cancer Thermal Therapy
Zhu, Y., Li, Q., Wang, C., Hao, Y., Yang, N., Chen, M., Ji, J., Feng, L., & Liu, Z. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00822 · Cited by 163
The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy
El-Awady, R., Saleh, E., Hashim, A., Soliman, N., Dallah, A., Elrasheed, A., & Elakraa, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00535 · Cited by 162
“…a variety of mechanisms that living cells may naturally have (intrinsic) or can develop from their environment or genetic changes (acquired) that give them the adaptation to resist foreign chemicals including chemotherapy (Swanton, 2012; Holohan et al., 2013; Blair et al., 2014; Chen et al., 2014).”
BackgroundFan, H.-Y., Yu, X.-H., Wang, K., Yin, Y.-J., Tang, Y.-J., Tang, Y.-L., & Liang, X.-H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111620 · Cited by 162
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives
Khatoon, E., Banik, K., Harsha, C., Sailo, B. L., Thakur, K. K., Khwairakpam, A. D., Vikkurthi, R., Devi, T. B., Gupta, S. C., & Kunnumakkara, A. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.014 · Cited by 159
Metabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy
Xie, S., Sun, W., Zhang, C., Dong, B., Yang, J., Hou, M., Xiong, L., Cai, B., Liu, X., & Xue, W. (2021) · ACS Nano · doi:10.1021/acsnano.1c00380 · Cited by 163
Photodynamic Therapy for Metastatic Melanoma Treatment: A Review
Naidoo, C., Kruger, C. A., & Abrahamse, H. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818791795 · Cited by 160
“Therefore, apoptosis is a regulated process that is induced.(50) Necrosis is a nonprogrammed mode of cell death that is characterized by inflammatory responses, which are initiated from external stimuli such as infections or trauma.”
BackgroundZeng, M., Guo, D., Fernández‐Varo, G., Zhang, X., Fu, S., Ju, S., Yang, H., Liu, X., Wang, Y., Zeng, Y., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00882 · Cited by 177
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy
Domoto, T., Pyko, I. V., Furuta, T., Miyashita, K., Uehara, M., Shimasaki, T., Nakada, M., & Minamoto, T. (2016) · Cancer Science · doi:10.1111/cas.13028 · Cited by 160
Dong, X., Yin, W., Zhang, X., Zhu, S., He, X., Yu, J., Xie, J., Guo, Z., Yan, L., Liu, X., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b17506 · Cited by 158
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.